The trial, which involved 847 intensive care unit (ICU) patients who had been undergoing invasive mechanical ventilation for at least 3 days, showed that a 3-day course of inhaled amikacin reduced the ...

Clinical question: Does inhaled amikacin reduce the incidence of ventilator-associated pneumonia (VAP) in critically ill patients? Background: VAP is a common and serious complication in patients on ...

The Company continues to anticipate that the totality of its early-stage research programs will comprise less than 20% of overall expenditure.

ARIKAYCE ® (amikacin liposome inhalation suspension) Delivers Full-Year 2023 Revenues Exceeding the Upper End of Guidance Range with Unaudited Global Net Product Sales of Approximately $305.2 Million— ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Insmed (INSM – Research Report), with a price target of $98.00.

ARIKAYCE ® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million-- --NDA for ...